Accumulation of amyloid fibrils in the viscera and connective tissues causes systemic amyloidosis, which is responsible for about one in a thousand deaths in developed countries 1 . Localized amyloid can also have serious consequences; for example, cerebral amyloid angiopathy is an important cause of haemorrhagic stroke. The clinical presentations of amyloidosis are extremely diverse and the diagnosis is rarely made before significant organ damage is present 1 . There is therefore a major unmet need for therapy that safely promotes the clearance of established amyloid deposits. Over 20 different amyloid fibril proteins are responsible for different forms of clinically significant amyloidosis and treatments that substantially reduce the abundance of the respective amyloid fibril precursor proteins can arrest amyloid accumulation 1 . Unfortunately, control of fibrilprotein production is not possible in some forms of amyloidosis and in others it is often slow and hazardous 1 . There is no therapy that directly targets amyloid deposits for enhanced clearance. However, all amyloid deposits contain the normal, non-fibrillar plasma glycoprotein, serum amyloid P component (SAP) 2, 3 . Here we show that administration of anti-human-SAP antibodies to mice with amyloid deposits containing human SAP triggers a potent, complement-dependent, macrophage-derived giant cell reaction that swiftly removes massive visceral amyloid deposits without adverse effects. Anti-SAP-antibody treatment is clinically feasible because circulating human SAP can be depleted in patients by the bis-D-proline compound CPHPC 4 , thereby enabling injected anti-SAP antibodies to reach residual SAP in the amyloid deposits. The unprecedented capacity of this novel combined therapy to eliminate amyloid deposits should be applicable to all forms of systemic and local amyloidosis.
SAP is selectively concentrated in amyloid deposits by its avid binding to all amyloid fibril types 2,3 . SAP binding stabilizes amyloid fibrils, protects them from proteolysis in vitro 5 and contributes to the pathogenesis of systemic amyloidosis in vivo 6 . Therefore, we developed a new bis-D-proline compound, (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC), which is bound with high affinity by human SAP and triggers its rapid clearance by the liver, thereby depleting circulating SAP by more than 90% for as long as the drug is administered 4, 7 . However, some SAP remains bound to amyloid even after months of CPHPC treatment 7 . Here we show that targeting this residual SAP with immunoglobulin-G (IgG) antibodies triggers the body's potent phagocytic clearance mechanisms (Supplementary Information, section 1).
Splenic and hepatic amyloid A protein (AA) amyloid deposition, closely resembling human systemic AA amyloidosis, was induced by chronic inflammation in C57BL/6 mice deficient in mouse SAP but transgenic for human SAP 4 . Human SAP is present in their circulation, in normal extracellular matrix 8, 9 (Supplementary Information, section 2) and in the amyloid deposits (Supplementary Information, section 3), just as in humans. Amyloid was quantified in each mouse by wholebody retention of 125 I-SAP (ref. 10) and the mice were allocated to three groups closely matched for age, sex and amyloid load. The model closely reflects clinical amyloidosis because human SAP binds much more avidly to amyloid than does mouse SAP 10 , and CPHPC depletes circulating human but not mouse SAP in vivo 4 . Two groups of mice then received CPHPC at 1 mg ml 21 in their drinking water for the rest of the experiment. Circulating human SAP was depleted but, as in humans treated with CPHPC, significant amounts of SAP remained in the amyloid deposits (Supplementary Information, section 4). Five days after starting on CPHPC, one group received a single intraperitoneal injection of 50 mg of the IgG fraction of monospecific polyclonal sheep antihuman-SAP antiserum, containing 7 mg of anti-SAP antibody. A control group received 50 mg of unrelated sheep IgG ( Supplementary  Information, section 4 ). The third group received no treatment and thus controlled for spontaneous regression of AA amyloid 11 . Twenty-eight days after the antibody or control IgG injection, the visceral amyloid load was scored histologically and human SAP was quantified in the individual sera and organs (Supplementary Information, section 4).
There was markedly less amyloid after treatment with CPHPC plus anti-SAP antibody than in the other two groups but there was no difference between CPHPC alone and no treatment ( Fig. 1 and Supplementary Information, section 4). Apart from the amyloid deposits there were no other significant histological abnormalities in any animal. Anti-SAP antibody thus produced remarkable regression of amyloid with no disruption to the normal parenchymal or connective-tissue structure of the liver, spleen or other organs. Furthermore, there were no clinical or biochemical adverse effects, no mice died during the experiment and body weights remained constant (Supplementary Information, section 5).
Systemic amyloid deposits are characteristically acellular with no surrounding inflammatory reaction (Figs 2l, p, 3a). However, by 24 h after injection of anti-SAP antibody all the deposits were densely infiltrated with mononuclear inflammatory cells and some granulocytes ( Fig. 2b , m, q). Most infiltrating cells stained strongly with antibody to F4/80, a global macrophage marker ( Fig. 2b ). No such staining was present in the amyloid deposits of mice not receiving anti-SAP. On day 2, the macrophages surrounding the amyloid were fusing to form multinucleate giant cells and stained strongly for CD68, a marker of phagocyte endocytotic activity that co-localized with staining for the amyloid fibril AA protein and mouse complement component C3 (Figs 2e-k, 3b, c and Supplementary Information, section 6). By day 4 the deposits were less abundant and were fragmented by numerous multinucleate giant cells surrounding and engulfing islands of amyloid ( Fig. 2c -e, n, r). At day 7, residual amyloid was mostly being degraded within the cytoplasm of decreasing numbers of giant cells. Amyloid clearance was largely complete by about day 16 with remarkable restoration of normal tissue architecture and absence of any residual cellular infiltrate ( Fig. 2o, s) .
Human SAP binds avidly to mouse AA deposits in vivo and persists there with a half-life of 3-4 days, whereas circulating human SAP is cleared in mice with a half-life of 3-4 h and is undetectable in the plasma after 3 days 4, 10 . Amyloid deposits in non-transgenic AA amyloidotic C57BL/6 mice were thus loaded with human SAP by a single intraperitoneal injection of 10 mg of the isolated pure protein and antihuman-SAP antibody was injected 3 days later without the need for CPHPC. The same highly reproducible amyloid elimination occurred as in the human SAP transgenic mice and this approach facilitated analysis of the mechanisms responsible.
In contrast to the clearance of amyloid deposits in wild-type mice, significantly more amyloid remained after anti-SAP treatment of complement-deficient animals lacking either C1q (ref. 12) or C3 (ref. 13) ( Supplementary Information, section 7) , demonstrating that the antibody effect is largely complement dependent. IgG antibody alone could potentially engage phagocytic cells via their Fcc receptors and, although amyloid clearance was much reduced in the absence of complement, the persistent deposits in complement-deficient mice were more fragmented than in untreated controls, indicating some direct antibody effect. There was more complete amyloid elimination 
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in some C1q-deficient mice than in C3-deficient mice ( Supplementary  Information, section 7) , indicating that complement activation may occur in the absence of C1q but that C3 is critical. Consistent with this observation, F(ab) 2 anti-SAP-antibody treatment reduced amyloid load but was significantly less effective than intact IgG antibody ( Supplementary Information, section 8 ). F(ab) 2 antibodies activate the alternative pathway, independently of C1q, and it is likely that the high dose of F(ab) 2 that was used (Supplementary Information, section 8) triggered some complement activation. Full efficacy of the anti-SAP antibody thus requires the Fc region but cellular recognition by Fcc receptors is not a major factor as F(ab) 2 was more effective in complement-sufficient mice than IgG antibody was in complementdeficient mice. When macrophage activity was ablated using liposomal clodronate 14 , anti-SAP antibody produced no reduction of amyloid load ( Supplementary Information, section 9 ), demonstrating that macrophages were the essential final effectors of amyloid clearance. Macrophages are largely responsible for the normal, clinically silent resolution of non-infective tissue injury and for remodelling of noncellular matrix. The failure to spontaneously clear amyloid depositswhich are composed only of autologous constituents-is therefore remarkable, especially as, despite their inherent stability, amyloid fibrils can be digested by proteinases and phagocytic cells in vitro 5 , particularly when opsonised by antibody 15 . In vivo macrophage responses to different types of amyloid have been reported occasionally [16] [17] [18] [19] , and amyloid deposits sometimes regress when fibril-precursor-protein abundance is sufficiently reduced 20, 21 . However, amyloid usually accumulates with little or no local cellular or systemic inflammatory response. The serendipitous effect of CPHPC in depleting circulating SAP but leaving some SAP in amyloid deposits enabled the present use of 
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anti-SAP antibodies to trigger unprecedented, clinically silent elimination of visceral amyloid deposits by macrophages. The same therapeutic approach should be effective in human amyloidosis, using human or humanized monoclonal antibodies or other antibody constructs. Therefore we investigated two of our mouse monoclonal IgG2a anti-SAP antibodies, designated SAP-5 and Abp1, which bound to human SAP with similar affinities, on rates and off rates ( Supplementary Information, section 10) , which activated mouse complement in vitro producing C3 cleavage comparable to that produced by the sheep polyclonal anti-human SAP, and which had similar plasma half lives of ,4 days in wild-type C57BL/6 mice. IgG2a antibodies were selected because mouse IgG1 activates mouse complement poorly if at all 22 . SAP-5 and Abp1 recognized different epitopes on human SAP (Supplementary Information, section 10) but were each as potent as the polyclonal sheep anti-SAP in eliminating amyloid in vivo ( Supplementary Information, sections 11 and 12 ).
Anti-SAP antibody could potentially elicit tissue-damaging inflammation in amyloidotic tissues. However, the present notable absence of any adverse effects presumably reflects the physiological nature of the macrophage reaction and is encouraging for the clinical use of CPHPC and anti-SAP. Nevertheless, appropriate caution will be essential because systemic amyloidosis patients have widespread amyloid deposits in sensitive tissues, including the heart, blood-vessel walls and nerves, which are not involved in the mouse AA model. Also, the trace amount of human SAP in normal glomerular basement membrane 8 and elastic fibre microfibrils 9 is a potential undesirable target for anti-SAP antibodies. It is therefore reassuring that there was no change in plasma biochemistry or any histological abnormality in human SAP transgenic mice treated with CPHPC followed by antihuman SAP antibodies ( Supplementary Information, section 13 ).
Antibodies to amyloid b-protein (Ab) are under intense investigation for the treatment of Alzheimer's disease and an in vivo imaging study 23 has shown binding to some human systemic immunoglobulin-lightchain amyloid (AL) deposits by a monoclonal anti-light-chain antibody that produces clearance of artefactual local human AL amyloidomas in mice 24, 25 . However, therapeutic anti-fibril antibodies will have to be reactive with each different type of amyloid whereas anti-SAP-antibody treatment is applicable to all forms of amyloidosis and all human amyloid deposits. Because the SAP that is universal in amyloid is derived from the circulation, anti-SAP antibodies and complement proteins will also be able to reach the deposits, and macrophages are present in, or can access, all tissues. Management of systemic amyloidosis will always require maximum efforts to reduce amyloid-fibril-precursor-protein production, if that is feasible, but the capacity to eliminate existing amyloid deposits would be a major therapeutic advance. We are now working towards clinical evaluation of this approach, and a candidate monoclonal anti-SAP antibody has been fully humanized for the exploration of safety, efficacy and optimal clinical dosing.
METHODS SUMMARY
Induction of murine AA amyloidosis using amyloid enhancing factor and repeated casein injections, estimation of amyloid load in vivo and in vitro, and quantification of human SAP in serum and tissue extracts, were conducted as previously reported 4, 6, 10 . Sheep and mouse anti-human-SAP antibodies were raised by immunization with isolated pure human SAP 26 and mouse anti-human-SAP hybridomas were cloned by standard methods; Abp1 was produced by AbPro. Figure 3 | Electron micrographs of amyloid destruction after anti-SAPantibody treatment. a, Spleen and liver from a control AA amyloidotic mouse loaded with human SAP, which did not receive anti-SAP antibody, showing extracellular masses of fibrillar amyloid with the characteristic absence of any inflammatory cells or cellular reaction. Scale bars, 3 mm. b, Liver from an AA amyloidotic mouse loaded with human SAP, examined 5 days after administration of anti-SAP antibody, showing a multinucleate giant cell surrounding, internalizing and digesting large masses of amyloid. Scale bar, 5 mm. c, Anti-CD68 immunostain of spleen removed one day after administration of anti-SAP antibody to an AA amyloidotic mouse loaded with human SAP, showing a macrophage surrounding, infiltrating and ingesting amyloid. The dark peroxidase reaction product (white arrows) identifies phagolysosome fusion around internalized fragments of amyloid. Scale bar, 1 mm.
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